Effectiveness and adverse effect of intravenous lacosamide in nonconvulsive status epilepticus and acute repetitive seizures in childre

Not Applicable

Active, not recruiting

• Conditions: onconvulsive status epilepticus or acute repetitive seizures; Intravenous lacosamide; status epilepticus; acute repetitive seizures; epilepsy

• Registration Number: TCTR20180508004
• Lead Sponsor: Phramongkutklao hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2017-01-12
• Study Start: 2018-05-08
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: 11

Inclusion Criteria

1.patients with status epilepticus and/or acute repetitive seizures aged less than 18 years
2.patients who had uncontrollable seizures after first-line antiepileptic drug therapies
3.patients with a contraindication to first-line antiepileptic drugs (allergy to drugs, comorbidity, drug interaction, risk of side effects).

Exclusion Criteria

1.Lacosamide use within 1 month
2.Allergic to lacosamide
3.Pregnancy patients
4.Underlying disease of cardiac AV block

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
seizure outcome during i.v. LCM treatment at 24 hours and 1 week Comparison between frequency of seizure baseline 1 month and % of seizure reduction after i.v. LCM

Secondary Outcome Measures

Name	Time	Method
adverse effect of Lacosamide during i.v. LCM treatment at 24 hours and 1 week observation